Interventional Study on Smoking Reduction in Psychiatry

Launched by GCS-CCOMS · Apr 7, 2025

Keywords

ClinConnect Summary

This clinical trial, called the "Interventional Study on Smoking Reduction in Psychiatry," is focused on helping people with mental health conditions who smoke. Research shows that people with mental disorders tend to smoke more than others, which can lead to serious health issues and significantly shorter lifespans. The study aims to test an intervention called 'Tabapsy,' designed to support adults who are regular smokers and receiving care from mental health services. The main goal is to see if this program can help participants quit smoking for at least 7 days within three months.

To take part in the study, participants need to be adults aged 18 or older who smoke at least one cigarette a day and are being treated in outpatient psychiatric care. Those interested will need to give their consent and must be covered by health insurance. The trial is currently recruiting participants and will also look into how well the program works and its overall costs. Participants will have the opportunity to share their experiences through interviews, which will help improve the program's implementation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Regular smokers (at least one cigarette per day)
• • Followed in psychiatric ambulatory care at one of the participating sectors' CMPs
• • Adults (18 years or older)
• • Covered by the statuary health insurance
• • Who gave their informed consent to participate to the study
• Exclusion Criteria:
• • Users under guardianship or legal protection,
• • Psychological state incompatible with completing the questionnaire,
• • Persons with no command or understanding of the French language